

REFERENCES for Part VI

1. Champion RH, Burton JL, Ebling FJG. Textbook of Dermatology. 5th. Ed. Oxford: Blackwell Scientific Publications, 1992 pp. 965–968, 879–893, 999–1000, 888–892, 716–743, 1699–1744, 1851–1863.
2. Braun-Falco O, Plewig G, Wolff HH, Winkelmann RK. Dermatology. Berlin-Heidelberg: Springer-Verlag, 1991 pp. 156–159, 22–36, 125–129, 32–36, 716–743, 730–736.
3. Darmstadt GL, Lane PT. Impetigo: An overview. *Pediatric Dermatol* 11: 293–303, 1994.
4. Drug Facts and Comparisons. St. Louis: Wolters-Kluwer Co. 2003 Ed.
5. Erlich KS, Mills J. Chemotherapy for Herpes simplex virus infections; Medical staff conference. *West J Med* 1985;143:648–655.
6. Lever WF, Schaumburg-Lever G. Histopathology of the Skin. 6th. Ed. Philadelphia: J B Lippincott Company, 1983, pp. 364.
7. Solomon AR. New diagnostic tests for Herpes simplex and varicella zoster infections. *J Amer Acad Dermatol* 1988;18:18–221.
8. Goodyear HM, Wilson P, Cropper L et al. Rapid diagnosis of Herpes simplex infections using specific monoclonal antibodies. *Clin Exper Dermatol* 1994;19:294–297.
9. Nahass GT, Goldstein BA, Zhu WY et al. Comparison of Tzanck smear, viral culture, and DNA diagnostic methods in detection of Herpes simplex and varicella-zoster infection. *JAMA* 1992;268:2541–2544.
10. Brody I. Topical treatment of recurrent Herpes simplex and postherpetic erythema multiforme with low concentrations of zinc sulphate solution. *Br J Dermatol* 1981;104:191–194.
11. Busso M, Berman B. Antivirals in dermatology. *J Amer Acad Dermatol* 1995;32:1031–1040.
12. Chatis PA, Miller CH, Schragar LE, Crumpacker CS. Successful treatment with foscarnet of an acyclovir resistant mucocutaneous infection with Herpes simplex virus in a patient with acquired immunodeficiency syndrome. *NEJM* 1989;320:297–300.
13. Safrin S, Crumpacker C, Chatis P et al. A controlled trial comparing foscarnet with vidarabine for acyclovir resistant mucocutaneous Herpes simplex in the acquired immunodeficiency syndrome. *NEJM* 1991;325:551–55.
14. La Rossa D, Hamilton R. Herpes simplex infections of the digits. *Arch Surg* 1971;102: 600–603.
15. Sachs E, House RK. The Ramsay Hunt Syndrome. *Neurol* 1956;6:262–268.
16. Cockrell CJ. Cutaneous manifestations of HIV infection other than Kaposi's sarcoma: Clinical and histologic aspects. *J Amer Acad Dermatol* 1990;22:1260–1269.
17. Wood MJ, Johnson RW, McKendrick MW et al. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute Herpes zoster. *NEJM* 1994;330:896–900.
18. Famciclovir for Herpes zoster. *The Medical Letter* 1994;36:7–98.
19. Kishore–Kumar R, Max MB, Schafer SC et al. Desipramine relieves postherpetic neuralgia. *Clin Pharmacol Ther* 1990;47:305.
20. Whitley JJ, Gnann JW. Acyclovir: A Decade Later. *NEJM* 1992;327:782–789.
21. Balfour HH. Acyclovir therapy for Herpes zoster: advantages and adverse effects. *JAMA* 1986;255:387–388.
22. King RB. Topical aspirin in chloroform and the relief of pain due to Herpes zoster and postherpetic neuralgia. *Arch Neurol* 1993;50:1046–1053.
23. Leider M, Rosenblum M. A Dictionary of Dermatological Words, Terms and Phrases. New York-Toronto-London-Sydney: Mc Graw-Hill, 1968, pp. 9.

From: *Current Clinical Practice: Dermatology Skills for Primary Care: An Illustrated Guide*
D.J. Trozak, D.J. Tennenhouse, and J.J. Russell © Humana Press, Totowa, NJ

24. Karvonen SL. Acne fulminans: Report of clinical findings and treatment of twenty-four patients. *J Amer Acad Dermatol* 1993;28:572–579.
25. Leyden JJ. The treatment and management of acne. *J Internat Postgrad Med* 1991;4:11–16.
26. Layton AM, Cunliffe WJ. Guidelines for optimal use of isotretinoin in acne. *J Amer Acad Dermatol* 27 #6 1992;part 2:S2–S7.
27. Lehucher-Ceyrac D, Weber-Buisset MJ. Isotretinoin an acne in practice: A prospective analysis of 188 cases over nine years. *Dermatology* 1993;186:123–128.
28. Stainforth JM, Layton AM, Taylor JP, Cunliffe WJ. Isotretinoin for the treatment of acne vulgaris: Which factors may predict the need for more than one course? *Br J Dermatol* 1993;129:297–301.
29. Layton AM, Knaggs H, Taylor J, Cunliffe WJ. Isotretinoin for acne vulgaris—10 years later: A safe and successful treatment. *Br J Dermatol* 1993;129:292–296.
30. Knight AG, Vickers CFH. A follow-up of tetracycline-treated rosacea. *Br J Dermatol* 1975;93:577–580.
31. Wilkin JK. Vasodilator Rosacea. *Arch Dermatol* 1980;116:98.
32. The guide to drug eruptions. 6 th. Ed. Amsterdam: Free University Amsterdam; File of Medicines, 1995, pp. 6.
33. Wilkin JK. Rosacea: Pathophysiology and treatment. *Arch Dermatol* 1994;130:359–362.
34. Mertz GJ, Loveless MA, Kraus SJ, et al. Famciclovir for the suppression of genital herpes. Proceedings of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC: American Society for Microbiology; 1994. Abs. H3.
35. Patel R, Crooks JR, Bell AR, and the International Valacyclovir Study Group. Once daily valacyclovir for the suppression of recurrent genital herpes—the first placebo controlled clinical trial. The First European Congress of Chemotherapy. Glasgow, UK; 1996. Abs.
36. Tyring S, Barbarash RA, Nahlik JE, et al., and the Collaborative Famciclovir Herpes Zoster Study Group. Famciclovir for the treatment of acute Herpes zoster: Effects on acute disease and postherpetic neuralgia. *Ann Int Med* 1995;123 #2:89–96.
37. Kost RG, Straus SE. Postherpetic neuralgia—pathogenesis, treatment, and prevention. *NEJM* 1996;335:32.
38. Leyden JJ. Therapy for acne vulgaris. *NEJM* 1997;336:1156–1162.
39. Adapalene for acne. *The Medical Letter* 1997;39:19–20.
40. Topical penciclovir for Herpes labialis. *The Medical Letter* 1997;39:57–58.
41. Genital Herpes Simplex Virus (HSV) Infection. *Arch Dermatol* 1998;134:650–652.
42. Langenberg AGM, Corey L, Ashley RL et al. A Prospective Study Of New Infections With Herpes Simplex virus Type 1 And Type 2. *NEJM* 1999;341:1432–1438.
43. Lautenschlager S, Eichman A. Urethritis: an underestimated clinical variant of genital herpes in men? *J Amer Acad Dermatol* 2002;46:307–308.
44. Brown TJ, Yen-Moore A, Tyring SK. An overview of sexually transmitted diseases. Part I. *J Amer Acad Dermatol* 1999;41:511–529.
45. Drugs For Non-HIV Viral Infections. *The Medical Letter* 2002;44:9–11.
46. Corey L, Wald A, Patel R et al. Once-Daily Valacyclovir to Reduce the Risk of Genital Herpes. *NEJM* 2004;350:11–20.
47. Gnann JW, Whitley RJ. Herpes Zoster. *NEJM* 2001;2002;347:40–346.
48. Wolverson SE. *Comprehensive Dermatologic Therapy*. W B Saunders Company.
49. *Physicians Desk Reference*. Thomson 58th. Ed., 2004.
50. Skidmore R, Kovach R, Walker C et al. Effect of Subantimicrobial-Dose Doxycycline in the Treatment of Moderate Acne. *Arch Dermatol* 2003;139:459–464.
51. Russell JJ. Topical Therapy for Acne. *Am Family Physician* 2000;61:357–366.
52. Elewski BE, Fleisher Jr. AB, Pariser DM. A Comparison of 15% Azelaic Acid Gel and 0.75% Metronidazole Gel in the Topical Treatment of Papulopustular Rosacea. *Arch Dermatol* 2003;139:1444–1450.
53. Kimberlin DW, Rouse DJ. Genital Herpes. *NEJM* 2004;350:1970–1977.